|
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.7600 EUR | -1.30% |
|
-0.26% | +12.10% |
| 07-22 | Valbiotis Publishes Results of Reverse-It Clinical Study Evaluating Totum 63 in Nature Communications | CI |
| 06-29 | Valbiotis Raises EUR10 Million for Commercial Development, Working Capital | MT |
Company Valuation: Valbiotis
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Market Cap 1 | 66.56 | 44.66 | 62.05 | 23.96 | 16.42 | 18.22 | - |
| Change | - | -32.91% | 38.94% | -61.38% | -31.48% | 10.96% | - |
| Enterprise Value (EV) 1 | 52.33 | 31.01 | 43.91 | 18.1 | 12.83 | 19.42 | 16.12 |
| Change | - | -40.75% | 41.6% | -58.78% | -29.1% | 51.32% | -17% |
| P/E | -7.29x | -2.98x | -8.47x | -2.41x | -1.48x | -2.47x | -9.63x |
| PBR | 4.66x | 3.34x | 3.18x | - | - | - | - |
| PEG | - | -0.1x | 0.2x | -0.36x | 0.1x | 0.1x | 0.1x |
| Capitalization / Revenue | 24.7x | 15.9x | 9.11x | 5.16x | 15.7x | 4.73x | 1.37x |
| EV / Revenue | 19.4x | 11x | 6.45x | 3.9x | 12.3x | 5.04x | 1.22x |
| EV / EBITDA | -6.95x | -2.77x | -6.81x | -1.84x | -1.4x | -2.49x | -6.72x |
| EV / EBIT | -6.18x | -2.58x | -6.12x | -1.74x | -1.35x | -2.24x | -3.07x |
| EV / FCF | -7.01x | -3.33x | -5.43x | -1.55x | -1.57x | -2.1x | -1.61x |
| FCF Yield | -14.3% | -30% | -18.4% | -64.6% | -63.8% | -47.6% | -62% |
| Dividend per Share 2 | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - |
| EPS 2 | -0.94 | -1.21 | -0.59 | -0.63 | -0.47 | -0.312 | -0.08 |
| Distribution rate | - | - | - | - | - | - | - |
| Net sales 1 | 2.693 | 2.814 | 6.809 | 4.644 | 1.046 | 3.85 | 13.25 |
| EBITDA 1 | -7.534 | -11.17 | -6.444 | -9.836 | -9.198 | -7.8 | -2.4 |
| EBIT 1 | -8.475 | -12.03 | -7.18 | -10.42 | -9.494 | -8.65 | -5.25 |
| Net income 1 | -8.681 | -12.31 | -7.368 | -10.02 | -9.417 | -8.75 | -5.35 |
| Net Debt 1 | -14.23 | -13.65 | -18.14 | -5.861 | -3.586 | 1.2 | -2.1 |
| Reference price 2 | 6.8500 | 3.6000 | 5.0000 | 1.5200 | 0.6940 | 0.7700 | 0.7700 |
| Nbr of stocks (in thousands) | 9,717 | 12,405 | 12,409 | 15,763 | 23,656 | 23,657 | - |
| Announcement Date | 15/03/22 | 15/03/23 | 26/04/24 | 03/03/25 | 02/03/26 | - | - |
1EUR in Million2EUR
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.47x | 5.04x | -2.49x | - | 20.95M | |
| 21.25x | 6.51x | 14.24x | 1.5% | 56.54B | |
| 31.6x | 7.8x | 24.02x | 0.05% | 53.6B | |
| -17.91x | 4.18x | -7.32x | -.--% | 22.91B | |
| -38.06x | 12.21x | -36.05x | -.--% | 21.37B | |
| 25.45x | 4.98x | 13.18x | -.--% | 20.27B | |
| 24.28x | 4.73x | 15.36x | -.--% | 17.56B | |
| -737.38x | 35.03x | -3943.97x | -.--% | 14.75B | |
| 40.7x | 16.37x | 42.16x | 0.09% | 13.53B | |
| 16.73x | 4.82x | 11.24x | -.--% | 13.33B | |
| Average | -63.58x | 10.17x | -386.96x | 0.18% | 23.39B | |
| Weighted average by Cap. | -32.01x | 9.11x | -238.37x | 0.38% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- ALVAL Stock
- Valuation Valbiotis
Select your edition
All financial news and data tailored to specific country editions
